A novel therapeutic strategy against monocytic leukemia with deoxyadenosine analogs and adenosine deaminase inhibitors

Leukemia and Lymphoma

Volumn 42, Issue 5, 2001, Pages 953-962

  Honma, Y ^a  

^a SAITAMA CANCER CENTER   (Japan)

Author keywords

Adenosine deaminase inhibitor; Apoptosis; Deoxyadenosine analogs; Differentiation; Monocytic leukemia

Indexed keywords

9 (2 HYDROXY 3 NONYL)ADENINE; ADECHLORIN; ADECYPENOL; ADENOSINE DEAMINASE INHIBITOR; ALPHA INTERFERON; CALCITRIOL; CASPASE 3; CLADRIBINE; COFORMYCIN; CORTICOSTEROID; CYTARABINE; DAUNORUBICIN; DEOXYADENOSINE; DEOXYADENOSINE DERIVATIVE; DEOXYADENOSINE TRIPHOSPHATE; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; ISOCOFORMYCIN; MERCAPTOPURINE; METHOTREXATE; PENTOSTATIN; UNCLASSIFIED DRUG; VIDARABINE; VINBLASTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOSOL; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; ERYTHROID CELL; HISTIOCYTOSIS X; HUMAN; HUMAN CELL; INOCULATION; KIDNEY DISEASE; LEUKEMIA CELL; LIVER DYSFUNCTION; LYMPHOMA CELL; MONOCYTIC LEUKEMIA; MOUSE; NEUROTOXICITY; NONHUMAN; NUDE MOUSE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034852376     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190109097714     Document Type: Article

References (75)

1. Nucleoside analogs: Cellular pharmacology, mechanisms of action, and strategies for combination therapy
2. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerase, DNA primase, and ribonucleotide reductase
3. Human monocytoid leukemia cells are highly sensitive to apoptosis induced by 2′-deoxycoformycin and 2′-deoxyadenosine: Association with dATP-dependent activation of caspase-3
4. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria
5. Phamacokinetics of arabinosylcytosine
6. Studies of 9-β- D-arabinofuranosyladenine in man
7. A novel adenosine and Ara-A deaminase inhibitor, [4,5-d][1, 3]diazepin-8-ol
8. Isolation of 2′-deoxycoformycin and cordycepin from wheat bran culture of Aspergillus nidulans Y176-2
9. Isolation and properties of a vidarabine deaminase inhibitor. Co-vidarabine
10. Treatment of acute lymphoblastic leukemia with 2′-deoxycoformycin: Clinical and biochemical consequences of adenosine deaminase inhibition
11. 2′-Deoxycoformycin (pentostatin) for lymphoid malignancies
12. Adenosine deaminase deficiency in two patients with severely impaired cellular immunity
13. Amelioration of neurologic abnormalities after "enzyme replacement" in adenosine deaminase deficiency
14. Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines
15. Sensitivity of leukemic human null lymphocytes to deoxynucleosides
16. Biochemical basis for differential deoxyadenosine toxicity to T and B lymphoblasts: Role for 5′-nucleotidase
17. G1-phase arrest of cultured human leukemic T-cells induced by deoxyadenosine
18. The treatment of adult acute myeloid leukemia
19. Intensive post-remission chemotherapy in adults with acute myeloid leukemia
20. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia
21. A randomized study of high dose cytarabine in induction in acute myeloid leukemia
22. High dose cytosine arabinoside plus etoposide as initial treatment for acute myeloid leukemia: A single centre study
23. A randomized trial of induction chemotherapy plus high dose radiotherapy versus radiation alone in stage III non-small cell lung cancer N.
24. Infectious complications of patients undergoing therapy for acute leukemia: Current status and future prospects
25. Resistance of an adenosine kinase-deficient human lymphoblastoid cell line to effects of deoxyadenosine on growth, S-adenosylhomocysteine hydrolase inactivation, and dATP accumulation
26. Vidarabine and 2-deoxycoformycin as antileukemic agents against monocytic leukemia
27. Anti-leukemic efficacy of 2′-deoxycofor mycin in monocytic leukemia
28. Involvement of an ICE-like protease in Fas-mediated apoptosis
29. CPP32, a novel human apoptotic protein with homologue to Caenorhabditis elegans cell death protein ced-3 and mammalian interleukin-1β-converting enzyme
30. Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c
31. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis
32. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade
33. Role of cytochrome c and dATP/ATP hydrolysis in Apaf-1-mediated caspase-9 activation and apoptosis
34. Modulation of cell death by Bcl-XL through caspase interaction
35. Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation
36. Bax directly induces release of cytochrome c from isolated mitochondria
37. hsp27 as a switch between differentiation and apoptosis in murine embryonic stem cells
38. HSP27 inhibits cytochrome c-dependent activation of procaspase-9
39. Heat shock protein 70 inhibits apoptosis downstream of cytochrome c release and upstream of caspase-3 activation
40. Akt regulates cell survival and apoptosis at a postmitochondrial level
41. Autoactivation of procaspase-9 by Apaf-1 -mediated oligomerization
42. An Apaf-1/cytochrome c multimeric complexes is a functional apoptosome that activates procaspase-9
43. Caspase activation involves the formation of the aposome, a large (∼700 kDa) caspase-activating complex
44. Apaf-1 oligomerizes into biologically active ∼700 kDa and ∼1.4 MDa apoptosome complexes
45. Human CARD4 protein is a novel CED-4/Apaf-1 cell death family member that activates NF-KB
46. Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-κB
47. IAP family of proteins-suppressors of apoptosis
48. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition
49. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins
50. Myeloid and monocytoid leukemia cells have different sensitivity to differentiation inducing activity of deoxyadenosine analogs
51. 2′-Deoxycoformycin (DCF) and 9-β-D-arabinofuranosyladeni ne (Ara-A) in the treatment of refractory acute myelocytic leukemia
52. Successful treatment of two children with Langerhans'cell histiocytosis with 2′-deoxycoformycin
53. Clinical pharmacology of 9 - β-D-arabinofuranosyladenine in combination with 2′-deoxycoformycin
54. S-Adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2′-deoxycoformycin alone and in combination with 9-β-D-arabinofuranosyladenine
55. Phase I trial of 2′-deoxycoformycin (dCF) and adenine arabinoside (ara-A) in the treatment of hematologic malignancies in children
56. Lack of significant activity of 2′-deoxycoformycin alone or in combination with adenine arabinoside in relapsed childhood acute lymphoblastic leukemia
57. Second malignancies following treatment in non-Hodgkin's lymphoma
58. Second malignancies in patients with hairy cell leukemia in British Columbia: A 20-year experience
59. Association of myelodysplastic changes with purine analogues
60. Long-term outcome of patients with hairy cell leukemia treated with pentostatin
61. Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine
62. Second malignancies as a consequence of nucleoside therapy for chronic lymphoid leukemias
63. Tight-binding inhibitors-IV. Inhibition of adenosine deaminase by various inhibitors
64. Studies on inhibition of adenosine deaminase by isocoformycin in vitro and in vivo
65. Adechlorin, a new adenosine deaminase inhibitor containing chlorine
66. Adecypenol, a unique adenosine deaminase inhibitor containing homopurine and cyclopentene rings
67. Specificity of adenosine deaminase inhibitors
68. Adenosine-mediated killing of cultured epithelial cancer cells
69. Potent inhibition of muscle 5′-AMP deaminase by the nucleoside antibiotics coformycin and deoxycoformycin
70. In vitro metabolism of deoxycoformycin in human T lymphoid cells
71. Potentiation of cytotoxicity and antitumor activity of adenosine analogs by the adenosine deaminase inhibitor adecypenol
72. Induction of differentiation of human myeloid leukemia cells by 2′-deoxycoformycin in combination with 2′-deoxyadenosine
73. Adenosine analogs as possible differentiation-inducing agents against acute myeloid leukemia
74. 3 prolong survival time of mice inoculated with myeloid leukemia cells
75. 3: In vivo and in vitro effects on human preleukemic and leukemia cells